The Effect of Chitinase-3-Like Protein 1 (YKL-40) Levels in the Plasma of Babylon Women with Breast Cancer
DOI:
https://doi.org/10.46966/msjar.v5i2.208Keywords:
Key words: Chitinase-3-Like Protein 1, SPSS, ELISA.Abstract
Background: Breast cancer (BC) is a kind of cancer that starts in the breast. patients in addition to doctors are disturbed by survival prognosis. Besides, the prognostic factor has been the clinic pathological parameter linked to tumor consequences. Also, this cancer type possesses the biggest uprising rate of frequency as well as number two in rates of mortality in female’ cancers. migration of cancer cells starting the primary tumor and the invasion of cancer cells in the adjacent tissue are the primary steps in cancer metastasis. The present education aims to evaluate Chitinase-3-Like Protein 1 (YKL-40) levels in Babylon women with breast cancer and control groups. Material and methods: The case-control group was made up of 60 subjects, presumably healthy women, whereas the sick group was made up of 60 women with breast cancer. A study was conducted in Marjan Medical City, Imam Al-Sadiq Hospital, and AL-Hilla Teaching Hospital in Hilla City, between 2/11/2023 and April 29/4/2024. An ELISA was used to calculate the plasma concentrations that referred to Chitinase-3-Like Protein 1 (YKL-40). SPSS software was used to conduct the statistical analysis. Results: Despite a considerable increase in Chitinase-3-Like Protein 1 levels, with patients comparing it together with the control group (p < 0.05). Conclusion: women with breast cancer had considerably increased serum levels of Chitinase-3-Like Protein 1 levels. Based on the results of this investigation, this indicates the part of Chitinase-3-similar to Protein 1 as a prognostic marker within females with BC disease.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Khawla A. Shemran, Zainab Mohsen Najm, Zinah Abbass Ali, , Hawraa Mudheher Kadhim
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
